GRK2-targeting Compound 10 slows Alzheimer’s progression in mouse models

ETH Zurich researchers identified that inactivated GRK2 aggregates in dementia brains damage mitochondrial function and accelerate amyloid-beta production, creating a self-perpetuating cycle. They developed Compound 10 to prevent GRK2 aggregation, which improved mitochondrial energy, reduced amyloid-beta, and extended survival in Alzheimer’s mouse models, with additional systemic anti-aging benefits observed. The basic research is complete and a patent has been filed; industry partnership is sought to advance toward clinical development.